Literature DB >> 2046134

Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials.

S Yusuf1, J Wittes, J Probstfield, H A Tyroler.   

Abstract

A key principle for interpretation of subgroup results is that quantitative interactions (differences in degree) are much more likely than qualitative interactions (differences in kind). Quantitative interactions are likely to be truly present whether or not they are apparent, whereas apparent qualitative interactions should generally be disbelieved as they have usually not been replicated consistently. Therefore, the overall trial result is usually a better guide to the direction of effect in subgroups than the apparent effect observed within a subgroup. Failure to specify prior hypotheses, to account for multiple comparisons, or to correct P values increases the chance of finding spurious subgroup effects. Conversely, inadequate sample size, classification of patients into the wrong subgroup, and low power of tests of interaction make finding true subgroup effects difficult. We recommend examining the architecture of the entire set of subgroups within a trial, analyzing similar subgroups across independent trials, and interpreting the evidence in the context of known biologic mechanisms and patient prognosis.

Entities:  

Mesh:

Year:  1991        PMID: 2046134

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  157 in total

1.  The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals.

Authors:  J L Glennie; G W Torrance; J F Baladi; C Berka; E Hubbard; D Menon; N Otten; M Rivière
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

Review 2.  Design issues for drug epidemiology.

Authors:  A D McMahon; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

3.  Clinical trial minority recruitment: still an unmet need.

Authors:  Lemuel A Moyé
Journal:  J Natl Med Assoc       Date:  2002-04       Impact factor: 1.798

Review 4.  Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years.

Authors:  Morris Zwi; Hannah Jones; Camilla Thorgaard; Ann York; Jane A Dennis
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

Review 5.  Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review.

Authors:  C Meads; C Hyde
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

Review 6.  Issues in the reporting of epidemiological studies: a survey of recent practice.

Authors:  Stuart J Pocock; Timothy J Collier; Kimberley J Dandreo; Bianca L de Stavola; Marlene B Goldman; Leslie A Kalish; Linda E Kasten; Valerie A McCormack
Journal:  BMJ       Date:  2004-10-06

Review 7.  Optimising the economic efficiency of drug studies.

Authors:  M E Kitler
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

8.  Access survival amongst hemodialysis patients referred for preventive angiography and percutaneous transluminal angioplasty.

Authors:  Kevin E Chan; Timothy A Pflederer; David J R Steele; Michael P Lilly; T Alp Ikizler; Frank W Maddux; Raymond M Hakim
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-29       Impact factor: 8.237

Review 9.  Antiarrhythmic therapies for the prevention of sudden cardiac death.

Authors:  F A McAlister; K K Teo
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

10.  Discordant minimum inhibitory concentration analysis: a new path to licensure for anti-infective drugs.

Authors:  Dean Follmann; Erica Brittain; John H Powers
Journal:  Clin Trials       Date:  2013       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.